Rheumatology Search
Rheumatology Rheumatology
gout
GOUT
Gout is a condition that resulted from deposition of monosodium urate crystals in various tissues (eg joints, connective tissue, kidney).
The patient experiences acute and chronic arthritis, soft tissue inflammation, tophus formation, gouty nephropathy and nephrolithiasis.
Primary hyperuricemia is called when uric acid saturation arises without coexisting diseases or drugs that alter uric acid production and excretion.
While in secondary hyperuricemia there is an excessive uric acid production or diminished renal clearance that occurs as a result of a disease, drug, dietary product or toxin.

Introduction

  • Gout is a condition wherein increased uric acid or urate in the body, also called hyperuricemia, leads to deposition of monosodium urate monohydrate (MSU) crystals in various tissues (eg joints, connective tissue, kidney)
  • Hyperuricemia is a necessary precondition for the development of MSU crystal deposition but this has to be distinguished from gout, the clinical syndrome
  • Results in acute and chronic inflammation associated with changes in articular & periarticular structures
  • Affects up to 1-2% of adults & is the most common inflammatory arthritis in men
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Ofatumumab a safe, effective alternative in B cell–depletion therapy
3 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
Herpes zoster vaccine may be used in RA patients receiving cDMARD, low-dose GC
6 days ago
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
Infliximab superior to TNFi in treatment of patients with ankylosing spondylitis
4 days ago
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.